Loading filters...
50 results(scroll for more)
GeneralAll Stages2026
Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer.
Sandoval TA et al. Cancer Res. 2026
GeneralAll Stages2026
Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer.
Tang W et al. Gynecol Oncol. 2026
GeneralEarly (I-IIA)2026
Survival and patterns of failure in small cell neuroendocrine carcinoma of the cervix treated with definitive chemoradiotherapy.
O'Shea J et al. Int J Gynecol Cancer. 2026
GeneralEarly (I-IIA)2026
Adjuvant, neoadjuvant, and surgical treatment for locally advanced cervical cancer: a Bayesian network meta-analysis.
Mamede I et al. Int J Gynecol Cancer. 2026
Immunotherapyadvanced2026
The activity of immune checkpoint inhibitors in patients with recurrent cervical cancer developed in previously irradiated field: clinical and immunohistochemical investigations.
Mabuchi S et al. J Gynecol Oncol. 2026
GeneralAll Stages2026
Extended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study.
Ma J et al. J Gynecol Oncol. 2026
GeneralAll Stages2026
Prophylactic extended-field radiotherapy with concurrent chemotherapy for locally advanced cervical cancer: a propensity-score matching analysis.
Li L et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Longitudinal Profiling of Cervical Cancers Reveals Therapy-Induced Vulnerabilities Beyond the Checkpoint.
Klopp AH et al. Cancer Res. 2026
GeneralEarly (I-IIA)2026
Prognostic value and adjuvant treatment outcomes for the use of the JGOG prognostic model in early-stage intermediate-risk cervical cancer: a Korean Gynecologic Oncology Group study (KGOG 1028).
Kim U et al. J Gynecol Oncol. 2026
AntiangiogenicAll Stages2026
Pelvic radiotherapy combined with immunotherapy and chemotherapy for stage IVB cervical cancer: a retrospective study.
Zhou J et al. Int J Gynecol Cancer. 2026
GeneralEarly (I-IIA)2026
Postoperative conventional versus hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer: a prospective multicenter randomized phase III trial (POHIM_P3 trial).
Cho WK et al. J Gynecol Oncol. 2026
GeneralAll Stages2026
A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.
Ryu SY et al. ESMO Open. 2026
ImmunotherapyAll Stages2026
Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).
Ogasawara A et al. Gynecol Oncol. 2026
Immunotherapyadvanced2026
Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III-IVA cervical cancer in the United States.
Brand-Wiita S et al. Gynecol Oncol. 2026
GeneralAll Stages2026
Refinement in radiotherapy treatment for locally advanced cervical cancer: a historic perspective.
Caicedo-Martínez M et al. Int J Gynecol Cancer. 2026
GeneralEarly (I-IIA)2026
Optimal adjuvant radiotherapy strategy for cervical cancer: a multi-center database cohort study.
Bai F et al. Int J Gynecol Cancer. 2026
ImmunotherapyAll Stages2026
Gynecologic cancers in 2025: a year in review.
Arenhardt MP et al. Int J Gynecol Cancer. 2026
GeneralEarly (I-IIA)2025
Neuroendocrine cervical carcinomas: genomic insights, controversies in treatment strategies, and future directions: a NeCTuR study.
Salvo G et al. Int J Gynecol Cancer. 2025
GeneralAll Stages2025
Intensified radiochemotherapy with cisplatin and gemcitabine for cervical cancer in the modern era: a retrospective cohort study.
Riggenbach E et al. J Gynecol Oncol. 2025
Generaladvanced2025
Nimotuzumab plus concurrent chemoradiotherapy sequential maintenance treatment for locally advanced cervical squamous cell carcinoma (NOTABLE-306): a multicenter, prospective, randomized, double-blind, placebo-controlled trial.
Wei S et al. J Gynecol Oncol. 2025
GeneralEarly (I-IIA)2025
Evaluation of toxicity after radical hysterectomy or trachelectomy and post-operative pelvic intensity-modulated radiation therapy with concurrent chemotherapy for cervical cancer.
Manning-Geist BL et al. Int J Gynecol Cancer. 2025
Immunotherapyadvanced2025
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Lorusso D et al. Gynecol Oncol. 2025
GeneralAll Stages2025
Addition of chemotherapy to radiation is associated with improved survival in older patients with cervical cancer: a Surveillance, Epidemiology, and End Results database analysis.
Leetanaporn K et al. Int J Gynecol Cancer. 2025
GeneralAll Stages2025
Follow-up strategies for patients with cervical cancer who achieved complete response after definitive chemoradiotherapy.
Kim YJ et al. Int J Gynecol Cancer. 2025
GeneralAll Stages2025
The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
Kim YJ et al. Gynecol Oncol. 2025
Antiangiogenicadvanced2025
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.
Kim YM et al. J Gynecol Oncol. 2025
Antiangiogenicadvanced2025
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.
Lorusso D et al. Ann Oncol. 2025
AntiangiogenicAll Stages2025
Revision of quality indicators for cervical cancer and trend analysis of existing indicators in Japan.
Kakuwa T et al. J Gynecol Oncol. 2025
GeneralEarly (I-IIA)2025
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.
Ryu SY et al. Ann Oncol. 2025
Immunotherapyadvanced2025
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Oaknin A et al. Eur J Cancer. 2025
GeneralEarly (I-IIA)2025
Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).
Chase DM et al. Gynecol Oncol. 2025
GeneralAll Stages2025
Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study.
Hu L et al. J Gynecol Oncol. 2025
Antiangiogenicadvanced2025
Toripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214).
Li C et al. J Gynecol Oncol. 2025
Generaladvanced2025
Patterns of pembrolizumab use for recurrent cervical cancer.
Huang Y et al. Int J Gynecol Cancer. 2025
GeneralAll Stages2025
Significance of HPV status on tumor response and treatment outcomes in endocervical adenocarcinoma treated with definitive chemoradiotherapy: a retrospective study.
Baek JY et al. J Gynecol Oncol. 2025
ADCAll Stages2025
Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets.
He J et al. Int J Gynecol Cancer. 2025
GeneralEarly (I-IIA)2025
Clinical outcomes of external radiotherapy boost versus no boost to radiologically positive lymph nodes in FIGO stage IIIC cervical cancer.
Rishi KS et al. Int J Gynecol Cancer. 2025
GeneralEarly (I-IIA)2025
Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study.
Hardie AN et al. Eur J Cancer. 2025
Generaladvanced2025
Efficacy and safety of cisplatin combined with paclitaxel concurrent radiotherapy in patients with locally advanced cervical squamous cell carcinoma.
Feng T et al. J Gynecol Oncol. 2025
GeneralEarly (I-IIA)2025
Chemo-conization in Early-sTage cERvical caNcer >2 cm scheduled for fertilItY-sparing approach: an analysis of the ETERNITY project.
Bogani G et al. Int J Gynecol Cancer. 2025
GeneralEarly (I-IIA)2025
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.
Randall L et al. Gynecol Oncol. 2025
Antiangiogenicadvanced2025
Circulating human papillomavirus DNA sequencing as a biomarker of response in advanced cervical cancer.
Collier E et al. Int J Gynecol Cancer. 2025
Generaladvanced2025
Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation.
Seo A et al. Clin Cancer Res. 2025
GeneralAll Stages2025
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Leath CA et al. Gynecol Oncol. 2025
Generaladvanced2025
Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana.
MacDuffie E et al. Gynecol Oncol. 2025
Immunotherapyadvanced2025
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics.
Bujnak AC et al. Gynecol Oncol. 2025
Antiangiogenicadvanced2025
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc.
Takekuma M et al. J Gynecol Oncol. 2025
GeneralAll Stages2025
ARTIA-Cervix: a prospective trial of adaptive radiation therapy for cervical cancer.
Mayadev JS et al. Int J Gynecol Cancer. 2025
GeneralEarly (I-IIA)2025
Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer.
Agustí N et al. JAMA Oncol. 2025
GeneralAll Stages2024
Can surgery boost the survival benefit of chemoradiotherapy in T1b1-T2a1 stage cervical cancer with lymph node metastasis? A population-based study.
Wang Y et al. J Gynecol Oncol. 2024